Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (CRBU) is a clinical-stage biopharma leader advancing CRISPR-engineered allogeneic CAR-T cell therapies. This page aggregates official announcements, clinical trial milestones, and strategic developments related to its chRDNA technology platform.
Investors and researchers will find timely updates on Caribou's innovative pipeline programs targeting hematologic cancers and autoimmune diseases. Key focus areas include CB-010 for B-cell malignancies, CB-011 in multiple myeloma, and autoimmune applications of PD-1 knockout therapies.
The repository features press releases on clinical trial data, regulatory progress, intellectual property developments, and strategic collaborations. Content is organized to highlight scientific advancements while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to Caribou's latest CRISPR innovations and corporate announcements. Check regularly for updates on allogeneic cell therapy developments and their potential impact on treatment paradigms.
Caribou Biosciences (CRBU) reported Q4 and full-year 2022 results, highlighting ongoing progress in its clinical pipeline. As of December 31, 2022, the company held $317 million in cash and equivalents, sufficient to fund operations into 2025. The lead therapy, CB-010, showed promising results in treating relapsed/refractory B-cell non-Hodgkin lymphoma, with notable complete response rates. Recent advancements include the activation of clinical sites for CB-011 and the initiation of IND-enabling studies for CB-012, targeting acute myeloid leukemia. However, a net loss of $99.4 million for 2022 raises concerns.
Caribou Biosciences (Nasdaq: CRBU), a leader in CRISPR genome-editing, announced that its CEO, Rachel Haurwitz, will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:40 am EDT. This event will showcase Caribou's advancements in gene-editing technologies, particularly their innovative CRISPR hybrid RNA-DNA guides (chRDNAs), aimed at enhancing precision in genome editing. The live webcast can be accessed on Caribou's website, available for 30 days post-event. The company focuses on developing transformative therapies for serious diseases using its proprietary technology.
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, Ph.D., will participate in three upcoming investor conferences in February 2023. The conferences include the Guggenheim Oncology Conference on February 9 at 10:45 AM EST, the SVB Securities Global Biopharma Conference on February 14 at 5:00 PM EST, and Citi's 2023 Oncology Leadership Summit on February 22 at 2:00 PM EST. All events offer webcasts for attendees. Caribou is known for its next-generation CRISPR genome-editing platform, particularly its innovative chRDNA technology, enhancing precision in therapies for hematologic malignancies and solid tumors.
Caribou Biosciences, Inc. (Nasdaq: CRBU) will present a corporate update by CEO Rachel Haurwitz at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 am PST. A live webcast will be available on Caribou's website, with an archived version accessible for 30 days post-event. Caribou is focused on advancing CRISPR genome-editing technologies, specifically its chRDNA platform, to develop innovative therapies for cancer treatment.
Caribou Biosciences announced promising long-term results from the ongoing ANTLER Phase 1 trial for its allogeneic CAR-T therapy, CB-010, targeting relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). Twelve-month data show that 100% of patients in cohort 1 achieved a complete response, with two maintaining durable responses for up to 18 months. The FDA granted CB-010 RMAT and Fast Track designations, enhancing its development pathway. Currently, the trial is enrolling patients at a higher dose level, indicating positive progress in patient recruitment and potential therapeutic efficacy.
Caribou Biosciences, Inc. (Nasdaq: CRBU) has announced the target selection for its allogeneic anti-ROR1 CAR-NK cell therapy, CB-020, to be presented at the AACR-JCA Conference. The preclinical data suggests ROR1 could be a viable target for solid tumors, enhancing antitumor activity via innovative armoring strategies. These strategies aim to improve NK cell survival and efficacy against tough tumor environments. The research indicates significant tumor burden reduction with CB-020 compared to unmodified NK cells. This advancement highlights Caribou's utilization of its proprietary chRDNA CRISPR technology.
Caribou Biosciences (Nasdaq: CRBU) announced FDA has granted its CB-010 therapy both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). This therapy, the first allogeneic CAR-T with a PD-1 knockout, is undergoing the ANTLER Phase 1 trial. Three out of six patients had a durable complete response at six months. These designations aim to expedite development and regulatory review for promising treatments addressing significant patient needs.
Caribou Biosciences (CRBU) reported its Q3 2022 results, highlighting a strong financial position with $342.6 million in cash and marketable securities. The ANTLER Phase 1 trial for its lead therapy, CB-010, shows promising early safety and efficacy data for r/r B-NHL patients, with plans to share additional results by year-end. The company submitted an IND application for CB-011 targeting r/r MM and expects further milestones, including CB-020 target selection, in the upcoming months.
Caribou Biosciences (Nasdaq: CRBU) announced its participation in several upcoming investor conferences. Key events include:
- Barclays Gene Editing & Gene Therapy Summit on November 14, 2022
- Jefferies London Healthcare Conference on November 17, 2022
- 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022
- BofA Securities Biotech SMID Cap Conference on December 7, 2022
Webcasts of these presentations will be available for 30 days post-event on Caribou's website.
Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that its trial-in-progress abstract for the ANTLER Phase 1 clinical trial of CB-010, targeting relapsed or refractory B cell non-Hodgkin lymphoma, has been accepted for a poster presentation at the 64th ASH Annual Meeting from December 10-13, 2022, in New Orleans.
The presentation, by Dr. Susan O’Brien, will detail the trial design and objectives. CB-010 is an allogeneic CAR-T cell therapy employing CRISPR technology. The poster will be accessible on the ASH website and Caribou's website following the presentation.
FAQ
What is the current stock price of Caribou Biosciences (CRBU)?
What is the market cap of Caribou Biosciences (CRBU)?
